MarketPeel
Insider Trading Intelligence
CS

Carmine N. Stengone

CTNM
CEO AND PRESIDENT · CONTINEUM THERAPEUTICS, INC. · CIK 0001861519
FILING MIX · LIFETIME59%/41%
BUYS
13
SELLS
9
TOTAL VALUE
$305.0K
COMPANIES
2
ACTIVE SINCE
Sep 2023
HOLDINGS NOW
52,217
AVG SELL PX
$16.01
TRADE KIND
SHOWING 22 / 22
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Carmine N. Stengone, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+100.00%-5.46%-0.31%-5.16%-4.74%
14d3+66.67%-8.17%-0.26%-7.92%-6.76%
30d3+66.67%-11.23%-3.27%-7.96%-8.16%
60d3+100.00%-11.84%+5.13%-16.97%-20.98%
90d3+100.00%-7.83%+9.06%-7.38%-7.38%
180d3(2 pending)+0.00%-10.89%+1.76%-12.66%-12.66%
1y3(2 pending)+0.00%-24.58%+19.74%-44.32%-44.32%
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CTNM · 27,217 shares · as of Jun 30, 2026
0111,250222,500333,750445,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 13 buys / 9 sellsCOVERAGE · 12 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASE
CEO and President
2,500$1.26$3.1K27,217Jun 30, 2026Jul 1, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE
CEO and President
7,500281,930Jun 30, 2026Jul 1, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE
CEO and President
2,500118,417Jun 30, 2026Jul 1, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,000$16.01$160.1K17,217Jun 30, 2026Jul 1, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASE
CEO and President
7,500$1.01$7.6K24,717Jun 30, 2026Jul 1, 2026View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
25,00025,000Jun 10, 2026Jun 11, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE
CEO and President
2,700120,917Feb 25, 2026Feb 26, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,700$16.02$43.2K14,954Feb 25, 2026Feb 26, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASE
CEO and President
2,700$1.26$3.4K17,654Feb 25, 2026Feb 26, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASE
CEO and President
4,400$1.26$5.5K19,354Feb 24, 2026Feb 26, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,400$16.02$70.5K14,954Feb 24, 2026Feb 26, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE
CEO and President
4,400123,617Feb 24, 2026Feb 26, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE
CEO and President
400128,017Feb 11, 2026Feb 13, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
400$16.00$6.4K14,954Feb 11, 2026Feb 13, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASE
CEO and President
400$1.26$50415,354Feb 11, 2026Feb 13, 2026View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
445,000445,000Jan 30, 2026Jan 30, 2026View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
20,00020,000Apr 1, 2025Apr 2, 2025View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000300,000Jan 31, 2025Jan 31, 2025View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASE
1,250$3.68$4.6K1,250Sep 11, 2024Sep 12, 2024View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,7781,778Jul 1, 2024Jul 3, 2024View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
285,000285,000May 24, 2024May 29, 2024View →
KPRX
KIORA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
8,0008,000Sep 29, 2023Oct 3, 2023View →
Other insiders · CTNM
Loading peer insiders…
About this filer
CIK 0001861519
ROLE
CEO and President
PRIMARY
CTNM
COMPANIES
2
ACTIVE SINCE
Sep 2023
MARKETPEEL · /INSIDER/0001861519DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback